JP2016520077A - Ｅ１ｅ２ｈｃｖワクチン及び使用方法 - Google Patents

Ｅ１ｅ２ｈｃｖワクチン及び使用方法 Download PDF

Info

Publication number
JP2016520077A
JP2016520077A JP2016513459A JP2016513459A JP2016520077A JP 2016520077 A JP2016520077 A JP 2016520077A JP 2016513459 A JP2016513459 A JP 2016513459A JP 2016513459 A JP2016513459 A JP 2016513459A JP 2016520077 A JP2016520077 A JP 2016520077A
Authority
JP
Japan
Prior art keywords
polypeptide
hcv
hcv genotype
genotype
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2016513459A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016520077A5 (cg-RX-API-DMAC7.html
Inventor
マイケル ホートン
マイケル ホートン
ダレン ホックマン
ダレン ホックマン
ジョン エル． ロウ
ジョン エル． ロウ
マイケル ローガン
マイケル ローガン
ロルネ ディー． ティレル
ロルネ ディー． ティレル
Original Assignee
ザ ガバナーズ オブ ザ ユニバーシティ オブ アルバータ
ザ ガバナーズ オブ ザ ユニバーシティ オブ アルバータ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ガバナーズ オブ ザ ユニバーシティ オブ アルバータ, ザ ガバナーズ オブ ザ ユニバーシティ オブ アルバータ filed Critical ザ ガバナーズ オブ ザ ユニバーシティ オブ アルバータ
Publication of JP2016520077A publication Critical patent/JP2016520077A/ja
Publication of JP2016520077A5 publication Critical patent/JP2016520077A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016513459A 2013-05-15 2014-05-15 Ｅ１ｅ２ｈｃｖワクチン及び使用方法 Withdrawn JP2016520077A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361823712P 2013-05-15 2013-05-15
US61/823,712 2013-05-15
US201361887229P 2013-10-04 2013-10-04
US61/887,229 2013-10-04
PCT/IB2014/001972 WO2015132619A1 (en) 2013-05-15 2014-05-15 E1e2 hcv vaccines and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019087976A Division JP2019142962A (ja) 2013-05-15 2019-05-08 Ｅ１ｅ２ ｈｃｖワクチン及び使用方法

Publications (2)

Publication Number Publication Date
JP2016520077A true JP2016520077A (ja) 2016-07-11
JP2016520077A5 JP2016520077A5 (cg-RX-API-DMAC7.html) 2017-06-22

Family

ID=54054625

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2016513459A Withdrawn JP2016520077A (ja) 2013-05-15 2014-05-15 Ｅ１ｅ２ｈｃｖワクチン及び使用方法
JP2019087976A Withdrawn JP2019142962A (ja) 2013-05-15 2019-05-08 Ｅ１ｅ２ ｈｃｖワクチン及び使用方法
JP2021001926A Pending JP2021059596A (ja) 2013-05-15 2021-01-08 Ｅ１ｅ２ ｈｃｖワクチン及び使用方法
JP2022137454A Pending JP2022172244A (ja) 2013-05-15 2022-08-31 Ｅ１ｅ２ ｈｃｖワクチン及び使用方法
JP2024130501A Pending JP2024156917A (ja) 2013-05-15 2024-08-07 Ｅ１ｅ２ ｈｃｖワクチン及び使用方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2019087976A Withdrawn JP2019142962A (ja) 2013-05-15 2019-05-08 Ｅ１ｅ２ ｈｃｖワクチン及び使用方法
JP2021001926A Pending JP2021059596A (ja) 2013-05-15 2021-01-08 Ｅ１ｅ２ ｈｃｖワクチン及び使用方法
JP2022137454A Pending JP2022172244A (ja) 2013-05-15 2022-08-31 Ｅ１ｅ２ ｈｃｖワクチン及び使用方法
JP2024130501A Pending JP2024156917A (ja) 2013-05-15 2024-08-07 Ｅ１ｅ２ ｈｃｖワクチン及び使用方法

Country Status (8)

Country Link
US (3) US20210145963A9 (cg-RX-API-DMAC7.html)
EP (2) EP2996718B1 (cg-RX-API-DMAC7.html)
JP (5) JP2016520077A (cg-RX-API-DMAC7.html)
CN (2) CN112999344A (cg-RX-API-DMAC7.html)
AU (3) AU2014385320B2 (cg-RX-API-DMAC7.html)
CA (1) CA2909586C (cg-RX-API-DMAC7.html)
CL (1) CL2015003333A1 (cg-RX-API-DMAC7.html)
WO (1) WO2015132619A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016336150B2 (en) * 2015-10-08 2023-08-10 The Governors Of The University Of Alberta Hepatitis C virus E1/E2 heterodimers and methods of producing same
AU2017332854B2 (en) * 2016-09-21 2024-11-14 The Governors Of The University Of Alberta Hepatitis C virus immunogenic compositions and methods of use thereof
US10881726B2 (en) 2016-10-11 2021-01-05 The Governors Of The University Of Alberta Hepatitis C virus immunogenic compositions and methods of use thereof
CA3093314A1 (en) 2018-03-16 2019-09-19 The Governors Of The University Of Alberta Hepatitis c virus peptide compositions and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005502611A (ja) * 2001-06-29 2005-01-27 カイロン コーポレイション Ｈｃｖｅ１ｅ２ワクチン組成物
WO2007041432A2 (en) * 2005-09-30 2007-04-12 Novartis Vaccines And Diagnostics, Inc. Cross-neutralization of hcv with recombinant proteins
WO2009061739A1 (en) * 2007-11-06 2009-05-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Neutralization of hcv

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
EP0812593B8 (en) 1993-03-23 2010-11-10 SmithKline Beecham Biologicals S.A. Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
EP1167378B1 (en) 1994-07-15 2011-05-11 University of Iowa Research Foundation Immunomodulatory oligonucleotides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
WO1996004301A2 (en) 1994-07-29 1996-02-15 Chiron Corporation Novel hepatitis c e1 and e2 truncated polypeptides and methods of obtaining the same
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
ES2241042T3 (es) 1996-10-11 2005-10-16 The Regents Of The University Of California Conjugados de polinucleotido inmunoestimulador/ molecula inmunomoduladora.
EP1039935A4 (en) 1997-02-28 2005-04-27 Univ Iowa Res Found USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
WO1998040100A1 (en) 1997-03-10 1998-09-17 Ottawa Civic Loeb Research Institute USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT
CA2288374A1 (en) 1997-05-06 1998-11-12 Chiron Corporation Intracellular production of hepatitis c e1 and e2 truncated polypeptides
US6339068B1 (en) 1997-05-20 2002-01-15 University Of Iowa Research Foundation Vectors and methods for immunization or therapeutic protocols
CA2293489C (en) 1997-06-06 2009-09-29 The Regents Of The University Of California Inhibitors of dna immunostimulatory sequence activity
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
EP1279401B1 (en) 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
TR200002930T2 (tr) 1998-04-09 2000-12-21 Smithkline Beecham Biologicals S.A. Kolaylaştırıcı kompozisyonlar
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
US7357936B1 (en) 1998-10-16 2008-04-15 Smithkline Beecham Biologicals, Sa Adjuvant systems and vaccines
EP1162999B1 (en) 1999-03-19 2006-11-29 Glaxosmithkline Biologicals S.A. Vaccine against Streptococcus pneumoniae
WO2000062800A2 (en) 1999-04-19 2000-10-26 Smithkline Beecham Biologicals Sa Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
AU766635B2 (en) 1999-09-24 2003-10-23 Smithkline Beecham Biologicals (Sa) Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant
IL148672A0 (en) 1999-09-24 2002-09-12 Smithkline Beecham Biolog Use of combination of polyxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
US7348011B2 (en) * 2005-06-10 2008-03-25 Sudershan Biotech Ltd. Hepatitis C virus vaccine
WO2014060851A2 (en) * 2012-10-05 2014-04-24 The Governors Of The University Of Alberta Hepatitis c virus immunogenic compositions and methods of use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005502611A (ja) * 2001-06-29 2005-01-27 カイロン コーポレイション Ｈｃｖｅ１ｅ２ワクチン組成物
WO2007041432A2 (en) * 2005-09-30 2007-04-12 Novartis Vaccines And Diagnostics, Inc. Cross-neutralization of hcv with recombinant proteins
WO2009061739A1 (en) * 2007-11-06 2009-05-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Neutralization of hcv

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ＡＮＴＩＶＩＲＡＬ ＴＨＥＲＡＰＹ, vol. 11, no. 8, JPN6018007756, 2006, pages 1005 - 1014, ISSN: 0004104496 *
ＧＡＳＴＲＯＥＮＴＥＲＯＬＯＧＹ, vol. [online], JPN6018007754, 11 May 2013 (2013-05-11), pages 10 - 1053, ISSN: 0004104494 *
ＪＯＵＲＮＡＬ ＯＦ ＩＮＦＥＣＴＩＯＵＳ ＤＩＳＥＡＳＥＳ, vol. 204, no. 8, JPN6018007758, 2011, pages 1186 - 1190, ISSN: 0003752961 *
ＰＬＯＳ ＯＮＥ, vol. Ｖｏｌ．８，Ｎｏ．３，ｅ５９７７６, JPN6018007746, March 2013 (2013-03-01), pages 1 - 7, ISSN: 0004104492 *
ＰＲＯＣ．ＮＡＴＬ．ＡＣＡＤ．ＳＣＩ．ＵＳＡ, vol. 102, no. 12, JPN6019033403, March 2005 (2005-03-01), pages 4560 - 4565, ISSN: 0004104497 *
ＶＡＣＣＩＮＥ, vol. 28, no. 38, JPN6018007750, 2010, pages 6367 - 6373, ISSN: 0004104493 *
ＶＡＣＣＩＮＥ, vol. 29, no. 16, JPN6018007761, 2011, pages 2910 - 2917, ISSN: 0004104495 *

Also Published As

Publication number Publication date
AU2014385320B2 (en) 2019-10-10
CA2909586A1 (en) 2015-09-11
AU2022200747A1 (en) 2022-02-24
CN105263517B (zh) 2021-03-26
HK1216395A1 (en) 2016-11-11
WO2015132619A1 (en) 2015-09-11
US20210145963A9 (en) 2021-05-20
EP2996718B1 (en) 2020-01-15
JP2022172244A (ja) 2022-11-15
AU2020200216A1 (en) 2020-02-06
AU2014385320A1 (en) 2015-11-12
CN112999344A (zh) 2021-06-22
CA2909586C (en) 2021-08-31
JP2019142962A (ja) 2019-08-29
JP2024156917A (ja) 2024-11-06
EP2996718A4 (en) 2017-06-21
EP2996718A1 (en) 2016-03-23
US20230098265A1 (en) 2023-03-30
US20240316186A1 (en) 2024-09-26
CL2015003333A1 (es) 2016-09-30
JP2021059596A (ja) 2021-04-15
US20160067332A1 (en) 2016-03-10
EP3689375A1 (en) 2020-08-05
CN105263517A (zh) 2016-01-20

Similar Documents

Publication Publication Date Title
US20240316186A1 (en) E1e2 hcv vaccines and methods of use
US12202859B2 (en) Hepatitis c virus E1/E2 heterodimers and methods of producing same
US12005116B2 (en) Hepatitis C virus immunogenic compositions and methods of use thereof
WO2014060851A2 (en) Hepatitis c virus immunogenic compositions and methods of use thereof
HK1216395B (en) E1e2 hcv vaccines and methods of use
HK40120034A (en) Hepatitis c virus e1/e2 heterodimers and methods of producing same
HK40121294A (en) Hepatitis c virus immunogenic compositions and methods of use thereof
HK1255379B (en) Hepatitis c virus immunogenic compositions and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170510

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170510

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180307

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180907

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190626

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190626

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20190716

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20190830

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20200121